C3851001 A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-069399999 (PRMT5 Inhibitor) in Participants with Advanced or Metastatic Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Es

NCT03854227

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-069399999 (PRMT5 Inhibitor) in Participants with Advanced or Metastatic Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, Cervical Cancer and Bladder Cancer.

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Pfizer

The purpose of this study is to learn about the effects of the study drug PF_06939999 (study drug) taken alone or in combination with docetaxel.